Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a Basket Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Combination Therapy With the Anti CD19 Monoclonal Antibody Tafasitamab and the PI3Kδ Inhibitor Parsaclisib in Adult Participants With Relapsed/Refractory Non Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

NCT04809467 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT04809467
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04809467 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a Basket Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Combination Therapy With the Anti CD19 Monoclonal Antibody Tafasitamab and the PI3Kδ Inhibitor Parsaclisib in Adult Participants With Relapsed/Refractory Non Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Lead sponsor
Incyte Corporation
Phase
Phase 1/2
Overall status
Terminated
Start date
September 16, 2021
Completion date
October 22, 2024
Enrollment
54 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, non hodgkin lymphoma